BMJ  2006;332:562-563 (11 March), doi:10.1136/bmj.332.7541.562

Editorial

Treating refractory epilepsy in adults

The choice of drug or drug combinations is bewildering

The first 150 words of the full text of this article appear below.

Most adult patients with refractory epilepsy have partial (focal) seizures with or without secondary generalisation. During the 1970s and early 1980s studies showed that in 70-80% of adults with newly diagnosed epilepsy, seizures were controlled successfully by carefully monitored monotherapy with any of the four standard antiepileptic drugs—phenobarbital, phenytoin, carbamazepine, or sodium valproate—all of which seemed to have similar efficacy in partial epilepsy in later comparative trials of monotherapy.1-4 Furthermore, adding a second drug for patients with continuing seizures on optimum monotherapy led to modest benefit in no more than one third, a deterioration in seizure control or unacceptable toxicity in about a quarter, and no change in the rest.2 5

These studies led to important questions. Should patients unresponsive to the optimum use of the first drug be switched to alternative monotherapy or treated with polytherapy? If so, which drug or drug combination is appropriate?

Twenty years later these . . . [Full text of this article]

Edward Reynolds, honorary senior lecturer

Institute of Epileptology, King's College, London SE5 6PJ
(reynolds@buckles.u-net.com)


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

The influence of big pharma
R E Ferner
BMJ 2005 330: 855-856. [Extract] [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

Other things also matter to patients
Joanne M Shaw
bmj.com, 14 Mar 2006 [Full text]



Student BMJ

Asylum seekers' care

UK medical students have published unreleased government plans to restrict failed asylum seekers' access to medical care

www.student.bmj.com

Listen to the latest BMJ Interview